Ikarian Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ikarian Capital’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,218,671	Closed	-$301K	–	188
2026 Q1	$301K	Hold	1,218,671	–	–	0.02%	133
2025 Q4	$512K	Sell	1,218,671 -75,981	-6%	-$40.3K	0.04%	138
2025 Q3	$872K	Buy	1,294,652 +34,473	+3%	+$18.6K	0.09%	121
2025 Q2	$682K	Sell	1,260,179 -600,000	-32%	-$356K	0.13%	86
2025 Q1	$1.22M	Hold	1,860,179	–	–	0.15%	89
2024 Q4	$1.9M	Buy	+1,860,179	New	+$3.4M	0.26%	82

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Ikarian Capital's SGMO Position: Q2 2026 in Review

Ikarian Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 1,218,671 shares — an estimated $301K sold.

Ikarian Capital first reported a position in SGMO in Q4 2024 and held it in 6 quarters. The position peaked at $1.9M in Q4 2024. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Ikarian Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Ikarian Capital sold 1,218,671 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $301K.
Ikarian Capital first reported a position in SANGAMO THERAPEUTICS INC in Q4 2024 and held it in 6 quarters.
Ikarian Capital's SANGAMO THERAPEUTICS INC position peaked at $1.9M in Q4 2024.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.